Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant : The French guidelines from CTAFU
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To define guidelines for the management of renal cell carcinoma of the native kidney (NKRCC) in kidney transplant (KTx) recipients and renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients candidates for renal transplantation.
METHOD: A review of the literature following a systematic approach (Medline) was conducted by the CTAFU to report renal cell carcinoma epidemiology, screening, diagnosis and management in KTx candidates and recipients. References were assessed according to a predefined process to propose recommendations with the corresponding levels of evidence.
RESULTS: ESRD patients are at higher risk of RCC with a standardized incidence ratio of approximately 4,5 as compared with general population. NKRCC tumors occur in 1 to 3 % of KTx recipients with a 10 to 15-fold increased risk as compared with general population, especially in patients with acquired multicystic kidney disease. Most authors suggest yearly monitoring of the native kidneys using ultrasound imaging. Radical nephrectomy (either open or laparoscopic approach) is the preferred treatment of NKRCC in KTx recipients and RCC in ESRD. Surveillance in a valid option in small or cystic renal masses. In the localized setting, change in immunosuppressive therapy is not recommended besides perioperative avoidance of mTOR inhibitor to limit morbidity. CTAFU does not recommend a mandatory waiting time after nephrectomy for RCC in ESRD patients candidates for renal tranplantation when tumor stage<T3 and low ISUP grade. Follow-up modalities should follow recommendations in general population.
CONCLUSION: The French recommendations should contribute to improve management of NKRCC in KTx recipients and RCC in ESRD candidates for KTx, integrating oncological objectives in the context of kidney transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 31(2021), 1 vom: 11. Jan., Seite 18-23 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : carcinome rénal sur reins natifs chez le patient transplanté rénal ou en attente de transplantation |
|---|
| Beteiligte Personen: |
Goujon, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinome à cellules rénales |
|---|
| Anmerkungen: |
Date Completed 02.09.2021 Date Revised 02.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.04.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319872599 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319872599 | ||
| 003 | DE-627 | ||
| 005 | 20231225172358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.04.030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319872599 | ||
| 035 | |a (NLM)33423742 | ||
| 035 | |a (PII)S1166-7087(20)30685-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Goujon, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant |b The French guidelines from CTAFU |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : carcinome rénal sur reins natifs chez le patient transplanté rénal ou en attente de transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2021 | ||
| 500 | |a Date Revised 02.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To define guidelines for the management of renal cell carcinoma of the native kidney (NKRCC) in kidney transplant (KTx) recipients and renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients candidates for renal transplantation | ||
| 520 | |a METHOD: A review of the literature following a systematic approach (Medline) was conducted by the CTAFU to report renal cell carcinoma epidemiology, screening, diagnosis and management in KTx candidates and recipients. References were assessed according to a predefined process to propose recommendations with the corresponding levels of evidence | ||
| 520 | |a RESULTS: ESRD patients are at higher risk of RCC with a standardized incidence ratio of approximately 4,5 as compared with general population. NKRCC tumors occur in 1 to 3 % of KTx recipients with a 10 to 15-fold increased risk as compared with general population, especially in patients with acquired multicystic kidney disease. Most authors suggest yearly monitoring of the native kidneys using ultrasound imaging. Radical nephrectomy (either open or laparoscopic approach) is the preferred treatment of NKRCC in KTx recipients and RCC in ESRD. Surveillance in a valid option in small or cystic renal masses. In the localized setting, change in immunosuppressive therapy is not recommended besides perioperative avoidance of mTOR inhibitor to limit morbidity. CTAFU does not recommend a mandatory waiting time after nephrectomy for RCC in ESRD patients candidates for renal tranplantation when tumor stage<T3 and low ISUP grade. Follow-up modalities should follow recommendations in general population | ||
| 520 | |a CONCLUSION: The French recommendations should contribute to improve management of NKRCC in KTx recipients and RCC in ESRD candidates for KTx, integrating oncological objectives in the context of kidney transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Carcinome à cellules rénales | |
| 650 | 4 | |a Greffon rénal | |
| 650 | 4 | |a Kidney transplant | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a Transplantation rénale | |
| 700 | 1 | |a Verhoest, G |e verfasserin |4 aut | |
| 700 | 1 | |a Sallusto, F |e verfasserin |4 aut | |
| 700 | 1 | |a Branchereau, J |e verfasserin |4 aut | |
| 700 | 1 | |a Boutin, J-M |e verfasserin |4 aut | |
| 700 | 1 | |a Bessede, T |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, N |e verfasserin |4 aut | |
| 700 | 1 | |a Karam, G |e verfasserin |4 aut | |
| 700 | 1 | |a Badet, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bigot, P |e verfasserin |4 aut | |
| 700 | 1 | |a Bensalah, K |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, M-O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 31(2021), 1 vom: 11. Jan., Seite 18-23 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:11 |g month:01 |g pages:18-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.04.030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 11 |c 01 |h 18-23 | ||